Use of a low-dose steroid as an adjunct in the treatment, in mice, of severe sepsis caused by Burkholderia pseudomallei.
Human melioidosis caused by Burkholderia pseudomallei is a severe septic disease that is associated with high mortality, even under appropriate antibiotic treatment. The therapeutic effects of low-dose hydrocortisone plus ceftazidime, and of ceftazidime alone, have recently been investigated in the treatment of acute, severe sepsis caused by B. pseudomallei, both in normal BALB/c mice and in BALB/c mice with streptozotocin-induced diabetes. The mice were infected and then treated intravenously, from day 1 or day 2 post-infection, with saline (as a control, given twice daily for 10 days), low-dose hydrocortisone (given in twice-daily doses of 5 mg/kg, for 5 days) plus ceftazidime (given in twice-daily doses of 1200 mg/kg, for 10 days), or the same doses of ceftazidime alone. Although the infected, untreated mice all died within 14 days, almost all of the treated animals were still alive at the end of the follow-up, 30 days post-infection. The addition of the steroid appeared to have no benefit, with bacterial loads and plasma concentrations of tumour necrosis factor, aspartate aminotransferase, alanine aminotransferase and creatinine decreasing similarly in all the treated groups. The infected diabetic mice given hydrocortisone-ceftazidime from day 1 (but not those given just ceftazidime from day 1) showed an increase in their blood glucose concentrations. When infected mice were treated with the low-dose steroid and lower doses of the antibiotic (in twice-daily doses of 120-600 mg/kg), the steroid not only offered no apparent benefit but seemed to reduce survival. It therefore appears that low-dose hydrocortisone, as an adjunct to antibiotic treatment, does not provide benefit in the treatment of murine melioidosis and may have negative effects on human cases of the disease who have diabetes mellitus.
Panomket
P
P
Graduate School, Khon Kaen University, Khon Kaen 40002, Thailand.
Chetchotisakd
P
P
Sermswan
R W
RW
Pannengpetch
P
P
Wongratanacheewin
S
S
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D016957:Burkholderia pseudomallei; D002442:Ceftazidime / Q000008:administration & dosage*; D017024:Chemotherapy, Adjuvant / Q000379:methods; D015169:Colony Count, Microbial; D016207:Cytokines / Q000097:blood; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000150:complications; D004334:Drug Administration Schedule; D006854:Hydrocortisone / Q000008:administration & dosage*; D008297:Male; D008554:Melioidosis / Q000097:blood / Q000188:drug therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D016688:Mice, Inbred NOD; D011897:Random Allocation; D018805:Sepsis / Q000097:blood / Q000188:drug therapy* / Q000382:microbiology
D000900:Anti-Bacterial Agents; D016207:Cytokines; D002442:Ceftazidime; D006854:Hydrocortisone